We are live on ! Find out more
MYOK

MyoKardia, Inc. Common Stock
MYOK

Delisted

MYOK was delisted on the 16th of November, 2020.

194 hedge funds and large institutions have $2.3B invested in MyoKardia, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 73 increasing their positions, 60 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 20

22% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 60

9% more funds holding

Funds holding: 178194 (+16)

9% more call options, than puts

Call options by funds: $67.9M | Put options by funds: $62.4M

11% less funds holding in top 10

Funds holding in top 10: 98 (-1)

36% less capital invested

Capital invested by funds: $3.62B → $2.3B (-$1.32B)

Holders
194
Holders Change
+16
Holders Change %
+8.99%
% of All Funds
4.28%
Holding in Top 10
8
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-11.11%
% of All Funds
0.18%
New
38
Increased
73
Reduced
60
Closed
20
Calls
$67.9M
Puts
$62.4M
Net Calls
+$5.53M
Net Calls Change
+$15.8M
Name Holding Trade Value Shares
Change
Change in
Stake
FCMI
26
Foresite Capital Management III
California
$18.1M +$3.78M +58,970 +18%
GPP
27
Great Point Partners
Connecticut
$17.1M +$23.3M +364,163 New
DM
28
Deerfield Management
New York
$16.2M -$28.4M -442,591 -56%
VC
29
Vivo Capital
California
$15.6M +$21.4M +333,621 New
FCMI
30
Foresite Capital Management IV
California
$14.4M +$3.01M +47,030 +18%
Loomis, Sayles & Company
31
Loomis, Sayles & Company
Massachusetts
$14.4M +$114K +1,778 +0.6%
MWNA
32
Marshall Wace North America
New York
$14.3M -$9.6M -149,832 -33%
LGM
33
Logos Global Management
California
$14.1M +$4.42M +68,991 +30%
Charles Schwab
34
Charles Schwab
California
$13.4M +$332K +5,187 +2%
SC
35
Samlyn Capital
New York
$12M +$2.57M +40,093 +19%
JP Morgan Chase
36
JP Morgan Chase
New York
$11.5M +$2.39M +37,367 +18%
Goldman Sachs
37
Goldman Sachs
New York
$10.2M +$4.15M +64,834 +43%
Bank of New York Mellon
38
Bank of New York Mellon
New York
$9.55M -$509K -7,948 -4%
Two Sigma Advisers
39
Two Sigma Advisers
New York
$9.54M +$13M +203,400 New
N
40
Nuveen
North Carolina
$9.46M +$227K +3,550 +2%
PAMU
41
Pictet Asset Management (UK)
United Kingdom
$9.31M -$5.05M -78,845 -28%
Primecap Management
42
Primecap Management
California
$8.71M -$7.1M -110,826 -37%
RPAM
43
Rhenman & Partners Asset Management
Sweden
$8.44M -$1.92M -30,000 -14%
SI
44
Sofinnova Investments
California
$8.21M -$1.33M -20,753 -11%
Victory Capital Management
45
Victory Capital Management
Texas
$7.85M +$5.1M +79,516 +90%
RSCM
46
Rock Springs Capital Management
Maryland
$7.74M +$320K +5,000 +3%
Fidelity International
47
Fidelity International
Bermuda
$7.25M -$10M -156,386 -50%
NHAS
48
Novo Holdings A/S
Denmark
$7.12M +$7.78M +121,468 +400%
Morgan Stanley
49
Morgan Stanley
New York
$7.09M +$4.72M +73,723 +95%
VOYA Investment Management
50
VOYA Investment Management
Georgia
$6.07M -$1.68M -26,219 -17%

MYOK Hedge Fund Activity: Q1 2020 in Review

194 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in MyoKardia, Inc. Common Stock (MYOK) for Q1 2020, worth a combined $2.3B — down 36% from $3.62B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new MYOK positions and 20 closed out — a net gain of 18 holders — while 73 added to existing stakes and 60 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $32.1M. The largest seller was Farallon Capital Management, cutting an estimated $104M.

  • 194 institutional investors held MyoKardia, Inc. Common Stock (MYOK) as of Q1 2020, up from 178 in Q4 2019.
  • Funds reported $2.3B of MyoKardia, Inc. Common Stock stock for Q1 2020, down 36% quarter-over-quarter.
  • 38 funds opened new MyoKardia, Inc. Common Stock positions in Q1 2020 and 20 closed out, a net change of +18 holders.
  • The largest MyoKardia, Inc. Common Stock buyer in Q1 2020 was Janus Henderson Group, an estimated $32.1M added.
  • The largest MyoKardia, Inc. Common Stock seller in Q1 2020 was Farallon Capital Management, an estimated $104M sold.

Based on aggregated 13F filings for Q1 2020.